Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 08:30 ET | Source: Vivos Inc.

Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational...
April 15, 2025 08:30 ET | Source: Vivos Inc.

Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™

Kennewick, WA, April 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide...
December 23, 2024 08:30 ET | Source: Vivos Inc.

Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial

Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India....
October 18, 2024 08:30 ET | Source: Vivos Inc.

Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty...
September 30, 2024 08:30 ET | Source: Vivos Inc.

Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics

Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable...